Welcome to our dedicated page for Pulsenmore news (Ticker: PLSM), a resource for investors and traders seeking the latest updates and insights on Pulsenmore stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pulsenmore's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pulsenmore's position in the market.
Pulsenmore (NASDAQ: PLSM) announced an expansion of its home ultrasound activities in Israel through integration of its technology at Lis Maternity and Women's Hospital at Ichilov, a major women's and maternity care center. Lis joins other Israeli medical centers that use Pulsenmore devices as part of pregnancy monitoring pathways.
The company now operates three models in Israel: a nationwide service with remote medical interpretation via Clalit Health Services; a Hospital at Home model used in several hospitals; and a hybrid model for high-risk pregnancies that combines in-hospital monitoring with at-home ultrasound scans under medical guidance.
Pulsenmore (NASDAQ: PLSM; TASE: PLSM) received a new $1.27 million grant from the Israel Innovation Authority to fund its 12‑month SmartScan AI home-ultrasound R&D program. According to Pulsenmore, this brings total AI grants approved over the past month to about $1.6 million, supporting two programs with a combined scope of roughly $3.12 million.
SmartScan AI aims to use AI-powered real-time ultrasound analysis and dynamic guidance to help pregnant women independently perform home scans, reducing operator dependency and improving image quality. Development is expected to leverage data from more than 250,000 clinical scans and optimize models for fast, on-device Edge AI processing. The program targets applications in fetal monitoring, late-pregnancy visual feedback on fetal head position during pushing preparation, and ultrasound monitoring in fertility treatment. The new grant follows Pulsenmore’s July 2026 selection for a joint Israel Innovation Authority–Ministry of Health AI program focused on clinical workflow efficiency.
Pulsenmore (NASDAQ: PLSM; TASE: PLSM) has been selected for Israel’s Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority and the Ministry of Health, to lead a $1 million AI development project. The company will receive IIA funding to develop and clinically validate AI applications that improve workflow efficiency and scalability of its connected home ultrasound platform for pregnancy care.
Pulsenmore reports over 250,000 home ultrasound scans performed to date, creating a large real‑world prenatal dataset for AI training. The project includes collaboration with Beilinson Hospital, part of Clalit Health Services, to develop and clinically validate the new AI applications.
Pulsenmore (NASDAQ: PLSM) priced a $7.5 million private placement with a single healthcare-focused institutional investor. The deal covers 1,562,500 ordinary shares (or pre-funded warrants) plus warrants for 1,562,500 shares at a combined purchase price of $4.80, above the Nasdaq Minimum Price.
Warrants are immediately exercisable at $4.80 for five years. Closing is expected on or about June 26, 2026. Net proceeds are earmarked for marketing, commercialization, working capital and general corporate purposes.
Pulsenmore (NASDAQ: PLSM) announced a strategic partnership with Ouma Health to integrate its FDA-authorized home ultrasound platform into Ouma’s virtual maternity care model across the United States.
The collaboration targets underserved communities and maternal care deserts, aiming to extend prenatal ultrasound monitoring into patients’ homes and support future expansion with healthcare systems and payers.
Pulsenmore (NASDAQ: PLSM) reported full-year 2025 revenue of $12.5 million, a 374% increase versus 2024, driven largely by a $9.6 million one-time settlement with GE. Net loss improved to $5.0 million from $10.0 million in 2024. Total liquid assets were $21.7 million (including $7.0 million cash) as of Dec 31, 2025.
Key operational milestones include FDA clearance for remote-use prenatal ultrasound in the U.S., MDR/CE certification for the Pulsenmore Early-Screening pregnancy product in Europe, and initial U.S. commercial programs. Management will host a webcast today, March 30, 2026, at 8:30am ET to discuss results and business update.
Pulsenmore (NASDAQ: PLSM) will release full year 2025 financial results on March 30, 2026 at 8:30 a.m. Eastern Time and will host a conference call and webcast to review results, business highlights, and recent progress.
Management presenting includes Jonathan Adereth (Chairman), Dr. Elazar Sonnenschein (CEO), Eran Hirsh (CFO), and Mira Altmark-Sofer (VP Marketing). The live webcast link and replay will be available on the company's Investor Relations website.
Pulsenmore (NASDAQ: PLSM) announced a commercial services agreement with TLC Perinatal PA to incorporate Pulsenmore's Early Screening home ultrasound into a physician-directed hybrid prenatal care pathway in Maryland.
The agreement covers Silver Spring and Germantown sites and aims to combine home ultrasound, telehealth, and scheduled clinic visits to extend care beyond the clinic.
Pulsenmore (NASDAQ: PLSM) announced its first U.S. commercial engagement on Feb 2, 2026, following FDA clearance for its home pregnancy ultrasound product. The company signed a services agreement with the Center for Fetal Medicine & Women's Ultrasound (CFFM) in Los Angeles to provide Pulsenmore ES home ultrasound services.
The agreement enables remote prenatal monitoring for patients at a center that manages approximately 1,500 pregnancies per year, with the goal of reducing unnecessary diagnostic visits and expanding telehealth-driven prenatal care.
Pulsenmore (NASDAQ: PLSM) and Clalit Health Services signed a strategic commercial agreement to deploy Pulsenmore FC, an at-home follicular monitoring service, via Beilinson NEXT in Israel. The agreement is potentially valued at $4.5 million over five years following an 18‑month pilot, with ramp-up expected in the coming weeks. Pulsenmore will supply patient‑operated devices, a mobile app with real‑time guidance, and secure image transmission for remote clinical oversight. A June 2025 study at Beilinson reported a strong safety profile and high concordance with in‑clinic measurements. Pulsenmore ES holds FDA De Novo authorization and a separate binding order for 25,000 units was signed in October 2024. Pulsenmore FC is approved for commercial use in Israel.